[{"orgOrder":0,"company":"KGK Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Acacia Catechu","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"KGK Science \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"KGK Science \/ Not Applicable"},{"orgOrder":0,"company":"KGK Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"KGK Science \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"KGK Science \/ Not Applicable"},{"orgOrder":0,"company":"KGK Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KGK Science \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"KGK Science \/ Not Applicable"},{"orgOrder":0,"company":"KGK Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Aloe Vera","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"KGK Science \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"KGK Science \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by KGK Science

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cosmoprof
                          Not Confirmed
                          Cosmoprof
                          Not Confirmed

                          Details : UP360 is a naturally-derived extracts from both the Poria cocos mushroom and rosemary as well as Aloe vera gel powder. The UP360 produces antioxidant, anti-inflammatory, and immunomodulatory effects.

                          Brand Name : UP360

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 03, 2023

                          Lead Product(s) : Poria cocos Mushroom Extract,Rosemary Extract,Aloe vera

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Cosmoprof
                          Not Confirmed
                          Cosmoprof
                          Not Confirmed

                          Details : NM-1001 (psilocybin) reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-a...

                          Brand Name : NM-1001

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 18, 2023

                          Lead Product(s) : Psilocybine

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Cosmoprof
                          Not Confirmed
                          Cosmoprof
                          Not Confirmed

                          Details : Psilocybin reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-anxiety eff...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 14, 2023

                          Lead Product(s) : Psilocybine

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Cosmoprof
                          Not Confirmed
                          Cosmoprof
                          Not Confirmed

                          Details : UP446, a natural health ingredient developed by Unigen, contains Acacia catechu and Scutellaria baicalensis, botanicals with antioxidant and anti-inflammatory properties; however, this is the first study to examine these ingredients using a human vaccine...

                          Brand Name : UP446

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          December 06, 2022

                          Lead Product(s) : Acacia Catechu,Scutellaria Baicalensis

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank